Use this link to cite:
https://hdl.handle.net/2183/49102 Secretome analysis of human articular chondrocytes unravels catabolic effects of nicotine on the joint
Loading...
Identifiers
Publication date
Authors
Lourido Salas, Lucía María
Calamia, Valentina
Fernández-Puente, Patricia
Mateos, Jesús
Oreiro Villar, Natividad
Ruiz-Romero, Cristina
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Lourido L, Calamia V, Fernández-Puente P, Mateos J, Oreiro N, Blanco FJ, Ruiz-Romero C. Secretome analysis of human articular chondrocytes unravels catabolic effects of nicotine on the joint. Proteomics Clin Appl. 2016 Jun;10(6):671-80.
Type of academic work
Academic degree
Abstract
[Abstract] Purpose: Osteoarthritis (OA) is a degenerative joint pathology characterized by articular cartilage degradation that lacks from efficient therapy. Since previous epidemiological data show a high controversy regarding the role of smoking in OA, we aimed to evaluate the effects of nicotine (the most physiologically active compound of tobacco) on the joint.
Experimental design: Secretome analyses, based on metabolic labeling followed by LC-MALDI-TOF/TOF analysis, were carried out using an in vitro model of articular inflammation (primary human articular chondrocytes treated with interleukin-1β), and also on osteoarthritic cells. ELISA and Western blot assays were performed to verify some of the results.
Results: Nineteen proteins were altered by nicotine in the model of articular inflammation, including several cytokines and proteases. We confirmed the increased secretion by nicotine of matrix metalloproteinase 1 and two proposed markers of OA, fibronectin, and chitinase 3-like protein 1. Finally, four components of the extracellular matrix of cartilage were decreased by nicotine in OA chondrocytes.
Conclusions and clinical relevance: Our data contribute to a better understanding of the molecular mechanisms that are modulated by nicotine in cartilage cells, suggesting a negative effect of this drug on the joint.
Description
Editor version
Rights
This is the peer reviewed version of the article which has been published in final form at Proteomics - Clinical Applications. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.